Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has been launched in South Korea. Leqembi received the Ministry ...

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...

Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...

Eli Lilly stock popped on news President Joe Biden proposed Medicare and Medicaid pay for weight-loss drugs. Is LLY stock a ...

Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.

Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline ...

Our analysis of options history for Biogen BIIB revealed 12 unusual trades. Delving into the details, we found 25% of traders ...

The European Medicines Agency (EMA) has recommended market approval for Alzheimer’s antibody Leqembi (lecanemab), reversing ...

DelveInsight's "Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth ...